Moreover, compared to monotherapy of anti-CTLA-4 antibody, this combination treatment increased CD8+/CD4+ ratio in T cells and reduced the number of regulatory T cells and myeloid-derived suppressor cells within the tumor microenvironment, enhancing anti-tumor immunity (Li et al., 2016). This evidence concerns the gene CD8A and neoplasm.